v3.26.3
Condensed Consolidated Statements of Cash Flows - CHF (SFr)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Condensed Consolidated Statements of Cash Flows    
Net loss for the period SFr (3,456,418) SFr (3,314,028)
Adjustments for:    
Net gain on Neurosterix Transaction   (117,747)
Fair value of services received at zero cost recorded as income (17,639) (105,660)
Fair value of services received at zero cost recorded as other operating costs 17,639 105,660
Value of share-based services 14,032 44,098
Post-employment benefits (8,701) 2,003
Share of the net loss of associates 2,330,789 2,079,296
Depreciation 35,046 4,236
Finance cost net (5,555) 33,399
Decrease / (increase) in other financial assets 1,146 (498)
Decrease / (increase) in trade and other receivables 4,682 (22,926)
Increase in prepayments (221,154) (81,430)
Decrease in other current assets   7,967
Increase in payables and accruals 24,570 347,082
Increase in other liabilities 47,461  
Net cash used in operating activities (1,234,102) (1,018,548)
Cash flows used in investing activities    
Consideration from Neurosterix Transaction   57,673
Investment in Stalicla Ltd - preferred shares   (285,962)
Investment in Stalicla Ltd - derivative financial instruments   (509,067)
Net cash used in investing activities   (737,356)
Cash flows from financing activities    
Sale of treasury ADSs and shares 411,588 777,546
Cost paid on sale of treasury ADSs and shares (18,860) (25,897)
Movements under liquidity agreement (1,257) 517
Principal element of lease payment (34,208) (3,607)
Interest paid (2,131) (1,374)
Net cash from financing activities 355,132 747,185
Decrease in cash and cash equivalents (878,970) (1,008,719)
Cash and cash equivalents at the beginning of the period 1,638,612 3,341,738
Exchange difference on cash and cash equivalents 7,686 (32,025)
Cash and cash equivalents at the end of the period SFr 767,328 SFr 2,300,994